C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer
Status:
Completed
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
Patients with castrate resistant prostate cancer (CRPCA) with osseous metastatic disease
planning to undergo Ra-223 therapy may be eligible for this study. Positron emission
tomography (PET/CT) imaging will use the investigational radiotracer [11C]acetate. Imaging
will occur prior to Ra-223 therapy and after 2 cycles, in addition to standard of care
99mTcMDP bone scan at baseline and a research 99mTc-MDP bone scan post-therapy
Phase:
Early Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania